Flatiron Health

This Breast Cancer Awareness Month, Flatiron Health is marking a milestone: our Breast Cancer Panoramic dataset has surpassed one million patients, with real-world data spanning the full breast cancer continuum, from early-stage through metastatic disease. The dataset includes 97,000+ patients tracked from early to metastatic disease, 575,000+ HR+ patients, and 109,000+ HER2-positive patients, with ongoing HER2 ultra-low integration. That depth supports biomarker-defined cohort research, treatment sequencing analyses, and real-world comparator arm development, turning complexity into clarity for the subgroups that matter most. This milestone is a reminder that behind every data point is a person, and that this scale reflects the trust clinicians and patients place in Flatiron's network every day. https://lnkd.in/deqAtrHj

We're headed to the Association for Value-Based Cancer Care (AVBCC) conference next week, where Flatiron leaders Kate Estep, Cleo A. Ryals, PhD, and Ahmed Sawas will join three panels on the future of oncology care. From bridging the gap between research and routine patient care, to connecting fragmented data across providers, payers, and manufacturers, to leveraging real-world evidence in policy and access decisions - these conversations bring together clinical, industry, and policy leaders to tackle the challenges defining value-based cancer care.

Over 48,000 people are diagnosed with colorectal cancer in the UK every year. Yet, fragmented and largely unstructured data has long slowed down the research that could improve care and save lives. By working collaboratively with NHS partners, Flatiron Health UK is helping to change that. We're building a national dataset that reflects how care is actually delivered – updated every 3 months, with depth of variables needed to power research and improve patient care. At Leeds Teaching Hospitals NHS Trust, this approach is already succeeding by accelerating how quickly teams evaluate trial eligibility. By joining this effort, NHS organisations get access to highly curated patient data that power research and care, global benchmarking data from Flatiron’s to identify improvement opportunities, and income to reinvest in cancer services. Learn more about what this could mean for your organisation: https://lnkd.in/dCr3pvun

Two times more patients. Three new geographies. One consistent data model. Flatiron Health has expanded its global Panoramic datasets with AI-powered breast cancer and NSCLC real-world data across the UK, Germany, and Japan—the second multinational Panoramic launch, following January's prostate cancer debut. Built on the same common data model underpinning Flatiron's US breast cancer and NSCLC Panoramic datasets—spanning nearly 1.5M patients—these new datasets unlock 2x the patients previously available across both tumor types and geographies, validated against Flatiron's VALID framework and built by clinical teams local to each market. For HEOR, RWE, and Medical Affairs teams, that means consistent cohorts and comparable outcomes across markets—complexity turned into clarity, ahead of ESMO 2026. Learn more about the datasets: https://lnkd.in/d4sZheua

When ESR1 mutation testing wasn't routinely performed by the NHS, there was no UK patient data to build an external control arm for elacestrant's NICE submission. The evidence needed to satisfy the UK's PICO framework simply didn't exist locally. Menarini Stemline leveraged high-fidelity, US-based, multimodal #RWD from Flatiron Health and Foundation Medicine. With rigorous cross-border adjustments to account for population differences, the analysis demonstrated a clear outcome advantage for elacestrant: 7.4 vs. 4.6 months median PFS and 27.7 vs. 18.0 months in overall survival. In February 2025, NICE recommended elacestrant for NHS coverage. Locally-sourced data is often preferable — but it isn't always available. This case shows that research-ready #RWE, built to the right standard of quality and completeness, can fill critical evidence gaps and support HTA submissions across borders. Read the full case study: https://lnkd.in/dR5aRKsd

Flatiron’s VALID framework has laid the foundation for a more rigorous, transparent way to measure the quality of LLM-extracted data—not just at a single point in time, but continuously as models, data and clinical practice evolve. By establishing a consistent approach to evaluating whether AI-generated data are fit for purpose, VALID helps turn data quality into something that can be systematically measured, monitored and improved. A new editorial in JCO Clinical Cancer Informatics from Danielle Bitterman, Umit Topaloglu and Jeremy Warner reinforces the framework’s impact, pointing to VALID as a model for the continuous validation the oncology informatics field should adopt as a standard for LLM-based evidence generation. We’re grateful to see the work recognized and, more importantly, to see the conversation around rigorous, continuous validation moving forward. Read more here: https://lnkd.in/gX5eWC69

Looking forward to joining Lindsey B. Cotton, Sanjay Juneja, M.D., Mika Newton, and Clynt Taylor at SHIFT with TensorBlack for a conversation on what it actually takes to turn molecular results from PDF documents and fragmented records into actionable insights that truly help patients. We'll dig into the infrastructure needed, where things go wrong, what data quality is acceptable, and more! If you're at SHIFT, I'd love to connect before or after the session. #SHIFT2026 #TensorBlack, #AIinOncology #PrecisionOncology

As joint clinical assessment (JCA) reshapes oncology evidence requirements across Europe, one question keeps coming up: when can evidence generated in one country reliably inform decisions in another, and when can't it? On the 8th of October 2026, leading experts including Uwe Siebert from UMIT TIROL and Harvard T.H. Chan School of Public Health, Philani Mpofu from Flatiron Health, Grammati Sarri from Cytel, and Lindsey Powers Happ from GSK will tackle this head on discussing: • What methodological standards and data quality requirements determine when transportability can and cannot be reliably applied • Real-world examples of transporting outcomes across borders and the factors that make cross-country comparisons challenging • How evolving HTA and regulatory frameworks are shaping good practice standards for transportability analyses • How manufacturers are navigating JCA's single evidence package requirement and what greater HTA consistency could unlock If evidence strategy is part of your role, it's worth an hour of your time. 📅 Thursday 8th October 2026 | 9am ET · 2pm BST · 3pm CET 🔗 https://lnkd.in/girNWquz

For years, oncologists have debated whether tumor mutational burden (TMB) can reliably predict who benefits from immunotherapy. A new study, co-authored with Foundation Medicine using our joint Clinico-Genomic Database, just brought some of the clearest evidence yet—and it's earned the Journal for ImmunoTherapy of Cancer's (JITC) 2026 Outstanding Paper Award for Immunotherapy Biomarkers. The study looked at more than 8,000 patients across 24 cancer types—the largest real-world analysis of its kind. The takeaway: patients with higher TMB consistently lived longer on immunotherapy alone, reinforcing the FDA-approved threshold used to guide treatment decisions today. It's a meaningful step toward answering a question that's shaped immunotherapy practice for years. Congratulations to the team on this well-earned recognition. See the full list of 2026 JITC Award winners: https://lnkd.in/dZJbM-sY

Today, our COO Julia Morton joined leaders from Thyme Care and Starling Oncology at Deutsche Bank for a wide-ranging conversation about the future of oncology care. Julia shared Flatiron’s vision for a more connected oncology ecosystem - one where high-quality data, trusted AI and real-world evidence help researchers move faster, support clinicians at the point of care and ultimately improve outcomes for patients. Thank you to Deutsche Bank for convening this important discussion!